Finzati - Logo
GMAB logo

Genmab A/S

GMABBiotechnology
$33.60
-0.81 (-2.35%)
Current price
EarningsLatest report: Mar 31, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$21.46B
Growth
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 25.9%Positive free cash flow · 1.85Consistent free cash flow · 5/5Reasonable earnings multiple · 19.86Healthy liquidity · 2.02
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 7, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$33.60
Change-2.35%
Shares Out638.55M
Market Cap$21.46B
Enterprise Value$25.16B
52W Range20.23 - 35.43
Beta0.68
P/E26.13
P/S5.50
P/B3.78
P/FCF24.62
EV/Sales6.45

Investment DNA

How strong this company looks for long-term investors

69
out of 100
Business Quality
Margins, moat, returns
77/100
Financial Strength
Debt, cash, stability
88/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
68/100
Why this score
Stable or improving margins · 25.9%Positive free cash flow · 1.85Consistent free cash flow · 5/5Reasonable earnings multiple · 19.86Healthy liquidity · 2.02Negative growth trend

Analyst view

Analyst sentiment and price target

GMAB
Analyst sentiment
Based on 18 analyst votes · 2026-09-05
83/100
Bullish
Bullish
13
Hold
4
Bearish
1
Price Target
2026-08-07
Low
$32.00
Mean
$39.08
Median
$40.00
High
$43.00

Company Overview

IPO: 6/1/2009
Industry: Biotechnology
P/B i: 3.78
Debt / Equity i: 0.93
Operating Margin: 33.60%
Net Margin: 25.89%
ROE i: -
ROIC: -

Financial Health

Score18 / 20
Debt / Equity: 0.93
Current Ratio: 2.02
Quick Ratio: 2.01
Status: Strong
🧾

No insider activity

No recent insider transactions available.